National Bank Financial Comments on ProMetic Life Sciences Inc.’s Q3 2016 Earnings (PLI)
ProMetic Life Sciences Inc. (TSE:PLI) – Equities researchers at National Bank Financial reduced their Q3 2016 earnings per share (EPS) estimates for ProMetic Life Sciences in a note issued to investors on Monday. National Bank Financial analyst E. Leno now anticipates that the brokerage will earn ($0.03) per share for the quarter, down from their previous estimate of ($0.02). National Bank Financial also issued estimates for ProMetic Life Sciences’ FY2016 earnings at ($0.12) EPS and FY2017 earnings at ($0.09) EPS.
PLI has been the subject of several other research reports. Canaccord Genuity upped their price objective on shares of ProMetic Life Sciences from C$4.50 to C$4.75 and gave the company a “buy” rating in a research note on Friday. TD Securities reaffirmed a “speculative buy” rating and set a C$4.50 price objective on shares of ProMetic Life Sciences in a research note on Wednesday. Scotiabank reaffirmed an “outperform” rating and set a C$5.00 price objective on shares of ProMetic Life Sciences in a research note on Wednesday, August 10th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday, October 13th. Finally, CIBC dropped their price objective on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of C$4.84.
ProMetic Life Sciences (TSE:PLI) opened at 2.83 on Thursday. ProMetic Life Sciences has a 12 month low of $1.88 and a 12 month high of $3.62. The stock’s market capitalization is $1.71 billion. The stock’s 50 day moving average is $2.89 and its 200-day moving average is $2.94.
About ProMetic Life Sciences
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.